AstraZeneca (STU:ZEG) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEG AstraZeneca PLC STU:ZEG
88 GF Score
Price €138.25
GF Value €160.90
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:ZEG
88GF Score
AstraZeneca PLC STU:ZEG
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €138.25 is trading 14.1% below its estimated GF Value™ of €160.90. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for STU:ZEG:

  • Dividends Received:
  • GF Value™: €160.90 vs. price of €138.25 (14.1% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEG

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€138.25
Price
€160.90
GF Value